Home > Quotes > EBIO
EBIO

Eleven Biotherapeutics, Inc. Common Stock Quote & Summary Data

$0.78
*  
0.0879
10.13%
Get EBIO Alerts
*Delayed - data as of May 2, 2016  -  Find a broker to begin trading EBIO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    EBIO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Eleven Biotherapeutics, Inc. Common Stock Intraday Chart




Shares Traded

Trading Range

Intraday Last 52 Weeks
High $ 0.8679 $ 13.775
Low $ 0.7501 $ 0.2511

The current last sale of $0.78 is 210.63% Higher thanthe 52 week low.

P/E Ratio

Company Description (as filed with the SEC)

We are a preclinical stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that we apply to the discovery and development of protein therapeutics to treat diseases of the eye. Our therapeutic approach is based on the role of cytokines in diseases of the eye, our understanding of the structural biology of cytokines and our ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. Our most advanced product candidate, which is still in preclinical development, is EBI-031, which we designed, engineered and generated using our AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema, or DME, and uveitis.  ... More ...  

Risk Grade

Where does EBIO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?